Krsnaa Diagnostics Limited — PPTs, 12-05-2025: Investor Presentation

1. Financial Highlights:

Krsnaa Diagnostics posted 16% YoY revenue growth to ₹7172 mn and a 34% jump in EBITDA to ₹1958 mn, driving margins up by 370 bps to 27%. PAT grew 37% to ₹776 mn with margin improvement of 165 bps to 11%. EPS rose 36% to ₹23.6. Patient footfall increased 23% to over 19 million, while tests performed surged 38% to 614 million. The balance sheet shows equity of ₹8828 mn and moderate borrowings of ₹1655 mn. Trade receivables rose to ₹2777 mn, reflecting scale growth but requiring monitoring.

2. Strategic Initiatives & Growth Drivers:

The company aims to expand diagnostic touchpoints aggressively, with CT centers growing from 180 to 875 and patient collection centers from 3500 to 10,000 by FY27. Focus remains on underserved markets via integrated radiology and pathology, leveraging PPP tenders. Retail diagnostics is a key pillar, targeting to more than double outlets in Maharashtra, Assam, Odisha, and Punjab by FY27. Cost leadership and pricing disruption underpin profitability.

3. Business Developments:

Rapid scaling of the retail diagnostic network includes in-shop branding and wellness packages enhancing visibility. Over 600 B2B partnerships serve labs and hospitals, with a target of 3500 by FY27. The tele-radiology hub, accredited by NABH and CAP, supports quality differentiation. Ongoing tech and skill investments improve operational efficiency.

4. Market Position & Competitive Advantage:

Krsnaa is among the largest affordable diagnostics players in India, offering test prices 70-90% lower than competitors. Nationwide accreditations and presence in 18 states reinforce quality and scale. Leadership in tele-radiology and strong PPP integration create a defensible edge in an underpenetrated market.

5. Investor Implications:

Double-digit growth driven by operational leverage and network expansion indicates positive growth potential. PPP-backed and retail diagnostics offer scalable revenues. Investors should watch execution risks around aggressive capex, center ramp-ups, and receivables management. The focus on affordability and quality positions Krsnaa to capture India’s large diagnostics opportunity.